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Clinical PerspectiveWhat Is New?This is the first systematic review and meta‐analysis of randomized controlled trials comparing anesthetic strategies during endovascular treatment for acute ischemic stroke.This study demonstrates that general anesthesia is associated with better functional outcomes than conscious sedation during endovascular treatment for acute ischemic stroke.What Are the Clinical Implications?Our report shows that general anesthesia results in significantly higher rates of functional independence than conscious sedation in patients with ischemic stroke undergoing endovascular therapy.

Introduction {#jah34168-sec-0008}
============

Endovascular treatment is a standard‐of‐care therapy for severe acute ischemic stroke caused by large‐vessel occlusion, recommended by international guidelines.[1](#jah34168-bib-0001){ref-type="ref"}, [2](#jah34168-bib-0002){ref-type="ref"}, [3](#jah34168-bib-0003){ref-type="ref"}, [4](#jah34168-bib-0004){ref-type="ref"} The continuing debate has focused on best practice for endovascular therapy, including which anesthetic type results in the best outcomes. General anesthesia (GA) with intubation may be associated with less pain and movement and lower aspiration risk.[5](#jah34168-bib-0005){ref-type="ref"} Conscious sedation (CS) with the patient spontaneously breathing may be associated with less time and hemodynamic instability and lower ventilation‐associated‐complications risk.

Previous systematic review and meta‐analyses[6](#jah34168-bib-0006){ref-type="ref"}, [7](#jah34168-bib-0007){ref-type="ref"}, [8](#jah34168-bib-0008){ref-type="ref"}, [9](#jah34168-bib-0009){ref-type="ref"}, [10](#jah34168-bib-0010){ref-type="ref"}, [11](#jah34168-bib-0011){ref-type="ref"}, [12](#jah34168-bib-0012){ref-type="ref"} mainly included observational studies,[13](#jah34168-bib-0013){ref-type="ref"}, [14](#jah34168-bib-0014){ref-type="ref"}, [15](#jah34168-bib-0015){ref-type="ref"}, [16](#jah34168-bib-0016){ref-type="ref"} which reported worse outcomes from GA compared with CS during endovascular therapy. However, observational studies,[13](#jah34168-bib-0013){ref-type="ref"}, [14](#jah34168-bib-0014){ref-type="ref"}, [15](#jah34168-bib-0015){ref-type="ref"}, [16](#jah34168-bib-0016){ref-type="ref"} as well as post hoc analysis of randomized clinical trials (RCTs),[17](#jah34168-bib-0017){ref-type="ref"}, [18](#jah34168-bib-0018){ref-type="ref"}, [19](#jah34168-bib-0019){ref-type="ref"} experience selection bias because patients with more serious stroke are much more likely to be treated under GA. By contrast, individual RCTs were underpowered to detect significant differences in primary outcome, limited by small numbers of events.[20](#jah34168-bib-0020){ref-type="ref"}, [21](#jah34168-bib-0021){ref-type="ref"}, [22](#jah34168-bib-0022){ref-type="ref"} Considering the discrepancy and the limitation of previous studies, we conducted a systematic review and meta‐analysis of RCTs to compare the impact of GA with CS for patients with ischemic stroke undergoing endovascular therapy.

Methods {#jah34168-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethical approval was not required.

Protocol and Guidance {#jah34168-sec-0010}
---------------------

This systematic review and meta‐analysis was prepared concerning the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA),[23](#jah34168-bib-0023){ref-type="ref"} and the Cochrane Handbook for Systematic Reviews of Interventions. The protocol has been registered with the PROSPERO (International Prospective Register of Ongoing Systematic Reviews); registration number CRD42018103684.

Eligibility Criteria {#jah34168-sec-0011}
--------------------

Inclusion criteria were as follows: Population: adult participants (≥18 years) with acute ischemic stroke managed with endovascular treatment.Intervention: GA.Comparison intervention: CS or local anesthesia.Outcome: The primary outcome was functional independence (modified Rankin Scale scores of ≤2) at 90 days. Secondary outcomes were 90‐day mortality and successful recanalization (modified Thrombolysis in Cerebral Infarction 2b‐3) at 24 hours. Other secondary outcomes (safety outcomes) were symptomatic intracranial hemorrhage, anesthesiologic complication, interventional complication, 20% mean arterial pressure decrease, intensive care unit length of stay, pneumonia, and costs.Study design: RCT.

Exclusion criteria: We excluded post hoc analyses and duplicate reports.

Missing data: We contacted the authors of all unpublished studies as well as any published studies in which data were missing to confirm eligibility and obtain additional details.

Information Sources and Search Strategy {#jah34168-sec-0012}
---------------------------------------

With the assistance of a professional librarian, we searched Medline, EMBASE, and the Cochrane Library at the CENTRAL Register of Controlled Trials from inception to August 1, 2018. We also consulted clinical trial registries (ClinicalTrials.gov, European Union Clinical Trials Register, World Health Organization International Clinical Trials Registry Platform, Stroke Trials Registry, and ISRCTN (International Standard Randomize Controlled Trial Number) Registry). We also searched the references of RCTs, review articles, and systematic reviews on the same topic for eligible articles. We did not use any language restrictions.

For the search strategy, we used the following search terms in various combinations: *endovascular, intra‐arterial, intervention, embolectomy, thrombolysis, thrombectomy, ischemia, stroke, cerebrovascular accident, infarct, general anesthesia, conscious sedation, local anesthesia, controlled trials,* and *randomized controlled trial*. (Details of the search strategy are shown in Table [S1](#jah34168-sup-0001){ref-type="supplementary-material"}).

Study Selection {#jah34168-sec-0013}
---------------

Initially, 2 independent investigators (L.J. and Y.Z.) screened the titles and abstract level, and independently screened the full text of eligible studies. Disagreements were resolved via consensus and by a third author (F.F.). We contacted study authors to obtain missing information and unpublished data when needed to assess the inclusion criteria or when suitable data were not available.

Data Collection Process {#jah34168-sec-0014}
-----------------------

Two independent investigators (L.J. and Y.Z.) extracted data from the included RCTs into standardized collection forms. Disagreements were resolved via consensus and by a third author (F.F.).

Assessment of Risk of Bias and Quality of Evidence {#jah34168-sec-0015}
--------------------------------------------------

Two independent investigators (L.J. and Y.Z.) performed risk assessment using the Cochrane Collaboration risk of bias tool[24](#jah34168-bib-0024){ref-type="ref"}: sequence generation of the allocation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Each domain was assessed as either low, unclear, or high risk of bias.

We used the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach to rate the quality of evidence.[25](#jah34168-bib-0025){ref-type="ref"} We used detailed GRADE guidance to assess the overall risk of bias, inconsistency, imprecision, indirectness, and publication bias and summarized results in an evidence profile.

Data Synthesis {#jah34168-sec-0016}
--------------

All analyses were performed in Review Manager for Windows (RevMan, version 5.3, Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration). Data were abstracted from each study using results reported in an intention‐to‐treat approach.[26](#jah34168-bib-0026){ref-type="ref"} We calculated odds ratios (OR) and 95% CIs using the Mantel--Haenszel model. For rare events (\<5%), we used the Peto method. Statistical heterogeneity among trials was assessed by the Cochran Q test and I^2^ test, with I^2^ \<25% and \<50 representing low and high heterogeneity, respectively. The meta‐analysis was done using a random‐effects model regardless of the level of heterogeneity because the included trials differed meaningfully in clinical and methodological features. A 2‐tailed *P* value of \<0.05 was considered a criterion for statistical significance.

If a pooled analysis included 10 or more studies, we planned to use a funnel plot to explore the possibility of publication bias.

Sensitivity Analyses {#jah34168-sec-0017}
--------------------

To ensure that estimates remained stable, we conducted sensitivity analyses to examine the impact of using alternative analysis methods: (1) a random‐effects model using the inverse variance method, (2) a fixed‐effects model using the inverse variance method, (3) a fixed‐effects model using the Mantel--Haenszel method, (4) calculating the risk difference with a random‐effects model using Mantel--Haenszel model, and (5) calculating the risk ratios with a random‐effects model using the Mantel--Haenszel model.

Results {#jah34168-sec-0018}
=======

Study Selection {#jah34168-sec-0019}
---------------

The search strategy yielded 1049 manuscript abstracts (Figure [1](#jah34168-fig-0001){ref-type="fig"}). Eleven pertinent studies were identified and included in full‐text review. After review, 8 studies[13](#jah34168-bib-0013){ref-type="ref"}, [14](#jah34168-bib-0014){ref-type="ref"}, [15](#jah34168-bib-0015){ref-type="ref"}, [16](#jah34168-bib-0016){ref-type="ref"}, [27](#jah34168-bib-0027){ref-type="ref"}, [28](#jah34168-bib-0028){ref-type="ref"}, [29](#jah34168-bib-0029){ref-type="ref"}, [30](#jah34168-bib-0030){ref-type="ref"} were excluded because they did not meet the inclusion criteria (Table [S2](#jah34168-sup-0001){ref-type="supplementary-material"}). Three trials[20](#jah34168-bib-0020){ref-type="ref"}, [21](#jah34168-bib-0021){ref-type="ref"}, [22](#jah34168-bib-0022){ref-type="ref"} comprising 368 participants were included in the final analysis.

![Search strategy and final included and excluded studies.](JAH3-8-e011754-g001){#jah34168-fig-0001}

Study Characteristics {#jah34168-sec-0020}
---------------------

Tables [1](#jah34168-tbl-0001){ref-type="table"} and [2](#jah34168-tbl-0002){ref-type="table"} show the characteristics of the included trials and patients. All trials were conducted in Europe. Population sizes were similar, and ranged from 106 to 150. The main inclusion criteria were adults with ischemic stroke, higher National Institutes of Health Stroke Scale (NIHSS) score (\>10), and occlusion in the anterior circulation. Mean age ranged from 71 to 73 years, and NIHSS score from 16 to 20. The follow‐up period was 90 days across trials.

###### 

Descriptive Summary of Randomized Trials Characteristics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                    SIESTA[20](#jah34168-bib-0020){ref-type="ref"}                                                                                                                               AnStroke[21](#jah34168-bib-0021){ref-type="ref"}                         GOLIATH[22](#jah34168-bib-0022){ref-type="ref"}
  ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------------
  Recruitment period       2014--2016                                                                                                                                                                   2013--2016                                                               2015--2017

  Country                  Germany                                                                                                                                                                      Sweden                                                                   Denmark

  Centers                  1                                                                                                                                                                            1                                                                        2

  Number of patients       150                                                                                                                                                                          106                                                                      128

  Inclusion criteria                                                                                                                                                                                                                                                             

  Age (y)                  ≥18                                                                                                                                                                          ≥18                                                                      ≥18

  NIHSS                    \>10                                                                                                                                                                         ≥10 (right‐sided occlusion) or ≥14 (left)                                \>10

  Occlusion                Anterior circulation                                                                                                                                                         Anterior circulation                                                     Anterior circulation

  Time frame               NR                                                                                                                                                                           8 h                                                                      6 h

  Other                    NR                                                                                                                                                                           NR                                                                       mRS ≤2

  Exclusion criteria       Not clearly depict site of vessel occlusion;\                                                                                                                                Anesthesiologic concerns (airway, agitation, etc);\                      Intubated;\
                           Not an internal carotid artery or a middle cerebral artery;\                                                                                                                 Occlusion of posterior circulation;\                                     Coma;\
                           Intracerebral hemorrhage;\                                                                                                                                                   Intracerebral hemorrhage;\                                               Not living independently;\
                           Coma;\                                                                                                                                                                       Neurological recovery or recanalization before or during angiography;\   mRS \>2
                           Severe agitation at admission;\                                                                                                                                              mRS score ≥4;\                                                           
                           Loss of airway‐protective reflexes of at least absence of gag reflex, insufficient saliva handling, observed aspiration, vomiting, or a combination thereof at admission;\   Other comorbidity contraindicating embolectomy                           
                           Difficult airway;\                                                                                                                                                                                                                                    
                           Intolerance of certain medications for sedation or analgesia                                                                                                                                                                                          

  Thrombectomy technique   Stent retriever or direct thrombus aspiration                                                                                                                                Stent retriever or Amplatz GooseNeck snare                               Stent retriever, direct thrombus aspiration, or intra‐arterial thrombolysis

  Follow‐up, days          90                                                                                                                                                                           90                                                                       90

  Primary end point        Change in NIHSS score 24 h after intervention                                                                                                                                Difference in mRS scores at 3 mo                                         Infarct growth 48 to 72 h after intervention

  Secondary outcomes       mRS scores after 90 days, in‐hospital and 3‐mo mortality, peri‐interventional safety, and feasibility.                                                                       Composite of death, nonfatal stroke, TIA, or peripheral embolism         mRS scores after 90 days, time and blood pressure levels, and safety end points
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

mRS indicates modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; NR, not reported; TIA, transient ischemic attack.

###### 

Baseline Patient Characteristics and Treatment Parameters by Treatment Group Among Included Randomized Trials

                                                              SIESTA 2016[20](#jah34168-bib-0020){ref-type="ref"}   AnStroke 2017[21](#jah34168-bib-0021){ref-type="ref"}   GOLIATH 2018[22](#jah34168-bib-0022){ref-type="ref"}                                     
  ----------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------ ---------------- ---------------- ----------------
  Age, mean (SD) or median (IQR), y                           71.8 (12.9)                                           71.2 (14.7)                                             73 (65--80)                                            72 (66--82)      71.0 (10.0)      71.8 (12.8)
  Risk factors, N (%)                                                                                                                                                                                                                                                
  Women                                                       25 (34.2)                                             35 (45.5)                                               19 (42)                                                22 (49)          29 (44.6)        33 (52.4)
  Hypertension                                                53 (72.6)                                             54 (70.1)                                               27 (60)                                                22 (49)          39 (60.0)        32 (50.8)
  Atrial fibrillation                                         36 (49.3)                                             36 (46.8)                                               18 (40)                                                18 (40)          24 (36.9)        27 (42.9)
  Ischemic heart disease                                      NR                                                    NR                                                      9 (20)                                                 5 (11)           NR               NR
  Antiplatelet therapy                                        20 (28.1)                                             24 (32.9)                                               NR                                                     NR               NR               NR
  Hyperlipidemia                                              20 (27.4)                                             24 (31.2)                                               5 (11)                                                 7 (16)           NR               NR
  Diabetes mellitus                                           17 (23.3)                                             17 (22.1)                                               9 (20)                                                 7 (16)           9 (13.8)         9 (14.3)
  Smoking                                                     9 (12.3)                                              13 (17.1)                                               4 (9)                                                  8 (18)           20 (30.8)        20 (31.7)
  NIHSS score, mean (SD) or median (IQR)                      16.8 (3.9)                                            17.2 (3.7)                                              20 (15.5--23)                                          17 (14--20.5)    18 (13--21)      17 (15--21)
  Site of occlusion, N (%)                                                                                                                                                                                                                                           
  Internal carotid artery                                     1 (1.4)                                               9 (11.7)                                                15 (33)                                                10 (22)          14 (21.5)        13 (20.6)
  Middle cerebral artery                                      46 (63.0)                                             47 (61.0)                                               26 (58)                                                34 (76)          33 (50.8)        39 (61.9)
  Tandem                                                      26 (35.6)                                             21 (27.3)                                               4 (9)                                                  1 (2)            18 (27.7)        11 (17.5)
  Left hemisphere                                             45 (61.6)                                             42 (54.5)                                               26 (58)                                                17 (38)          39 (60.0)        32 (50.8)
  Converted to GA                                             ···                                                   11 (14.2)                                               ···                                                    7 (15.6)         ···              4 (6.3)
  Time from stroke onset, mean (SD) or median (IQR), minute                                                                                                                                                                                                          
  From stroke onset to door                                   145.0 (83.8)                                          118.1 (61.5)                                            NR                                                     NR               159 (122--230)   145 (113--231)
  From door to puncture                                       75.6 (29.3)                                           65.6 (19.9)                                             34 (18--47)                                            25 (15--36)      24 (20--27)      15 (12--20)
  Duration of EST                                             111.6 (62.5)                                          129.9 (62.5)                                            55 (38--110)                                           74 (37--104)     34 (21--51)      29 (16--51)
  From onset to reperfusion                                   NR                                                    NR                                                      254 (206--373)                                         250 (213--316)   212 (180--288)   216 (162--285)
  IV t‐PA, N (%)                                              46 (63.0)                                             50 (64.9)                                               33 (73.3)                                              36 (80)          50 (76.9)        46 (73.0)
  Types of endovascular treatment, N (%)                                                                                                                                                                                                                             
  Stent retriever                                             60 (82.2)                                             66 (85.7)                                               NR                                                     NR               14 (21.5)        12 (19.0)
  Direct aspiration                                           6 (8.2)                                               4 (5.2)                                                 NR                                                     NR               25 (38.5)        24 (38.1)
  Both                                                        16 (21.9)                                             12 (15.6)                                               NR                                                     NR               11 (16.9)        10 (15.9)

CS indicates conscious sedation; EST, endovascular stroke treatment; GA, general anesthesia; IQR, interquartile range; IV t‐PA, intravenous tissue plasminogen activator; NIHSS, National Institutes of Health Stroke Scale; NR, not reported.

Risk of Bias and Quality of Evidence {#jah34168-sec-0021}
------------------------------------

The overall risk of bias was moderate among studies (Figure [S1](#jah34168-sup-0001){ref-type="supplementary-material"}). The nature of the trial interventions precluded blinding of patients and their physicians; random sequence generation and blinding of outcome assessment were considered as low‐risk items across trials. GRADE summary findings for all outcomes are shown in Table [3](#jah34168-tbl-0003){ref-type="table"}. We did not use funnel plots to assess the existence of possible publication bias because there were only 3 RCTs included in our study.

###### 

Summary of Findings and Strength of Evidence

  Outcome                                     No. of Patients (Studies)   Relative Effect (95% CI)     I^2^   Illustrative Comparative Risks (95% CI, Per 1000)   Strength of Evidence (GRADE)                      
  ------------------------------------------- --------------------------- ---------------------------- ------ --------------------------------------------------- ------------------------------ ------------------ ----------------------------------------------------------------------------------------
  Functional independence (mRS scores 0--2)   368 (3)                     OR 1.87 (1.15--3.03)         17%    346                                                 497                            151 (32--270)      Moderate[a](#jah34168-note-0006){ref-type="fn"}
  Successful recanalization (mTIMI 2b‐3)      368 (3)                     OR 1.94 (1.13--3.35)         0%     757                                                 858                            101 (22--156)      Moderate[a](#jah34168-note-0006){ref-type="fn"}
  Mortality                                   368 (3)                     OR 0.74 (0.43--1.27          0%     205                                                 160                            −45 (−105 to 42)   Moderate[a](#jah34168-note-0006){ref-type="fn"}
  Interventional complications                368 (3)                     OR 1.76 (0.86--3.61)         0%     76                                                  126                            50 (−10 to 152)    Moderate[a](#jah34168-note-0006){ref-type="fn"}
  Symptomatic intracerebral hemorrhage        368 (3)                     OR 0.61 (0.14--2.71)         0%     32                                                  20                             −12 (−28 to 51)    Moderate[a](#jah34168-note-0006){ref-type="fn"}
  Anesthesiologic complications               368 (3)                     OR 1.02 (0.28--3.72)         24%    38                                                  39                             1 (−27 to 90)      Moderate[a](#jah34168-note-0006){ref-type="fn"}
  Pneumonia                                   240 (2)                     OR 1.76 (0.38--7.98)         66%    82                                                  135                            53 (−49 to 334)    Low[a](#jah34168-note-0006){ref-type="fn"} ^,^ [b](#jah34168-note-0007){ref-type="fn"}
  ICU length of stay                          150 (1)                     MD 17.10 (−13.44 to 47.64)   NR     NR                                                  NR                             NR                 Moderate[a](#jah34168-note-0006){ref-type="fn"}
  20% MAP decrease                            218 (2)                     OR 10.76 (5.25--22.07)       0%     444                                                 896                            451 (363--502)     Moderate[a](#jah34168-note-0006){ref-type="fn"}

CS indicates conscious sedation; GA, general anesthesia; ICU, intensive care unit; MAP, mean arterial pressure; MD, mean difference; mRS, modified Rankin Scale; NR, not reported; OR, odds ratio; TIMI, thrombolysis in myocardial infarction.

Imprecision because of the wide CI.

Inconsistency.

Efficacy of GA Versus CS {#jah34168-sec-0022}
------------------------

Figure [2](#jah34168-fig-0002){ref-type="fig"} shows the associations between GA versus CS and efficacy. Three trials reported outcomes of functional independence. Overall, 154 out of 368 patients (41.8%) achieved functional independence at 90 days. Patients receiving GA for endovascular therapy had a higher chance of achieving functional independence (OR 1.87, 95% CI 1.15--3.03, I^2^=17%). We did not present a funnel plot because there were only 3 trials.

![Forest plot of efficacy of all trials evaluating general anesthesia vs conscious sedation. **A**, Functional independence (modified Rankin Scale scores of ≤2) at 90 days. **B**, Successful recanalization (mTICI 2b‐3) at 24 hours. **C**, Mortality at 90 days: M‐H. M‐H indicates Mantel--Haenszel; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction.](JAH3-8-e011754-g002){#jah34168-fig-0002}

Rates of successful revascularization at 24 hours for GA were 85.2% versus 75.7% for CS (OR 1.94, 95% CI 1.13--3.3, I^2^=0%). Among the 3 trials, death occurred in 15.8% of patients among the GA group and 20.5% of patients among the CS group. There was no statistically significant difference between the 2 groups in mortality (relative risk 0.74, 95% CI 0.43--1.27, I^2^=0%).

Safety of GA Versus CS {#jah34168-sec-0023}
----------------------

Results of adverse events among both examined groups for all trials are detailed in Figure [3](#jah34168-fig-0003){ref-type="fig"}. Pooled estimates suggested that GA was associated with 20% mean arterial pressure decrease (OR 10.76, 95% CI 5.25--22.07). Other meta‐analyses showed no significant difference between anesthetic types in rates of symptomatic intracranial hemorrhage (OR 0.51, 95% CI 0.14--1.91), anesthesiologic complication (OR 1.03, 95% CI 0.35--3.03), interventional complication (OR 1.76, 95% CI 0.86--3.61), intensive care unit length of stay (mean difference 17.10, 95% CI −13.44 to 47.64), and pneumonia (OR 1.75, 95% CI 0.38--7.98). To date, no trial has reported quality of life.

![Forest plot of safety of all trials evaluating general anesthesia vs conscious sedation. **A**, Interventional complication. **B**, Symptomatic intracranial hemorrhage. **C**, Anesthesiologic complication. **D**, Pneumonia. **E**,ICU length of stay. **F**, 20% mean arterial pressure decrease. ICU indicates intensive care unit; IV inverse variance; M‐H, Mantel--Haenszel.](JAH3-8-e011754-g003){#jah34168-fig-0003}

Sensitivity Analyses {#jah34168-sec-0024}
--------------------

Similar results were observed for similar primary outcome in all conducted sensitivity analyses: (1) a random‐effects model using the inverse variance method (OR 1.87, 95% CI 1.15--3.03), (2) a fixed‐effects model using the inverse variance method (OR 1.88, 95% CI 1.21--2.92), (3) a fixed‐effects model using the Mantel--Haenszel method (OR 1.88, 95% CI 1.21--2.91), (4) calculating the risk difference with a random‐effects model using the Mantel--Haenszel model (risk difference 0.15, 95% CI 0.05--0.24), and (5) calculating the risk ratios with a random‐effects model using the Mantel--Haenszel model (risk ratio 1.38, 95% CI 1.01--1.88).

Discussion {#jah34168-sec-0025}
==========

In the present systematic meta‐analysis of data from 3 RCTs with 368 patients, GA compared with CS results in greater improvement in functional independence at 90 days after acute ischemic stroke. Furthermore, compared with CS, GA was associated with higher rates of successful recanalization at 24 hours but was associated with no significant differences in mortality or symptomatic intracranial hemorrhage.

Compared With Other Studies {#jah34168-sec-0026}
---------------------------

To the best of our knowledge, this study is the first meta‐analysis of only RCT evaluating CS versus GA for endovascular therapy for ischemic stroke. Previous meta‐analyses on this topic, mainly based on observational studies, suggested that GA compared with CS for endovascular therapy decreases neurological recovery and increases mortality and morbidity.[6](#jah34168-bib-0006){ref-type="ref"}, [7](#jah34168-bib-0007){ref-type="ref"}, [8](#jah34168-bib-0008){ref-type="ref"}, [9](#jah34168-bib-0009){ref-type="ref"}, [10](#jah34168-bib-0010){ref-type="ref"}, [11](#jah34168-bib-0011){ref-type="ref"}, [12](#jah34168-bib-0012){ref-type="ref"} A post hoc analysis of MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) showed that endovascular therapy with GA did not repeat the treatment benefit in MR CLEAN.[19](#jah34168-bib-0019){ref-type="ref"} The association of GA with worse outcomes after endovascular therapy in observational studies may be explained by blood pressure decreases and a longer delay of time to groin puncture in the GA group, both of which have been associated with worse endovascular treatment outcomes.[31](#jah34168-bib-0031){ref-type="ref"}

Contrary to numerous nonrandomized studies and previous meta‐analyses, this study seems to support the idea that endovascular treatment might be performed with greater technical success when patients are under GA. The difference between this study and previous studies might be explained by selection bias of observational studies since GA was often chosen for the patients with more severe illness. In those studies, average baseline NIHSS scores were higher for patients receiving GA than those receiving CS.[8](#jah34168-bib-0008){ref-type="ref"}

There are 3 RCTs to assess whether GA is superior to CS among patients receiving endovascular therapy for stroke. However, 3 trials had different primary outcomes (change in NIHSS at 24 hours, modified Rankin Scale at 3 months, and infarct growth 48--72 hours, respectively) and showed no significant differences in their primary outcomes. The first trial, SIESTA (Sedation versus Intubation for Endovascular Stroke Treatment), found GA versus CS did not result in greater improvement in neurological status in patients with ischemia undergoing endovascular thrombectomy (difference, −3.2 points \[95% CI, −5.6 to −0.8\]). The second one, AnStroke (Anesthesia During Stroke), showed no difference was found between GA and CS in neurological outcome 3 months after stroke (*P*=1.00). The last one, GOLIATH (General or Local Anesthesia in Intra Arterial Therapy), concluded GA did not result in worse tissue or clinical outcomes compared with CS. All primary outcomes failed partly because the small sample size may have limited study power to detect clinically relevant differences in outcomes. Interestingly, this meta‐analysis of those trials showed mostly positive effects of GA.

Contrary to previous studies,[10](#jah34168-bib-0010){ref-type="ref"}, [20](#jah34168-bib-0020){ref-type="ref"} we did not find a higher frequency of pneumonia in the GA group. Only 2 trials[20](#jah34168-bib-0020){ref-type="ref"}, [21](#jah34168-bib-0021){ref-type="ref"} with a total of 240 patients reported pneumonia. The limited information may be underpowered enough to evaluate safety. Observational studies may be more appropriate than trials to evaluate safety because these can involve more people than RCTs.

Future Research {#jah34168-sec-0027}
---------------

Future studies are needed to systematically study the relationship of disease‐, patient‐, and treatment‐related variables with outcomes following GA for endovascular therapy for the treatment of ischemic stroke, and to identify the ideal patient to undergo GA. Limits on age, GCS (Glasgow Coma Scale), NIHSS score, ASPECTS (Alberta Stroke Program Early CT Score), and, perhaps most importantly, time to treatment, need to be explored. Moreover, longer follow‐ups could help provide much more understanding of effectiveness and safety. Finally, cost‐effectiveness analyses should be pursued to ascertain the value of GA for endovascular therapy.

Strengths and Limitations {#jah34168-sec-0028}
-------------------------

To the best of our knowledge, this study is the first meta‐analysis that only involved RCT evaluating the anesthetic strategy of endovascular therapy, which avoided selection bias of retrospective studies and reduced imprecisions of small RCTs. Strengths of this meta‐analysis included performing a comprehensive search and duplicate assessment of citation screening, data abstraction, and risk of bias. The meta‐analysis implemented a rigorous assessment of the quality of evidence. We have evaluated relative and absolute risks, which are important for making decisions between GA and CS.

We are, however, aware of several limitations. First, our statistical analysis might be imprecise because the studies include relatively few patients and thus have wide CIs around the estimate of the effect, although pooled analysis of these studies yielded statistical significance of primary outcome with low statistical heterogeneity.

Second, the small number of involved RCTs afforded insufficient ability to detect the presence of publication bias.[32](#jah34168-bib-0032){ref-type="ref"}, [33](#jah34168-bib-0033){ref-type="ref"} However, publication bias is unlikely because all the RCTs had negative results in the primary outcome.

Third, all involved trials were conducted in developed countries, and the management of GA relies more on advanced physical facilities and technical means than CS. Thus, these findings may not apply to less developed countries. Further research in these countries would add to the generalizability.

Fourth, there was a high rate of conversion to GA in the CS group in the included trials (6.3%, 14.2%, 15.6%, respectively), perhaps induced by different strategies in the CS group (ie, monitored anesthetic care or traditional regional anesthesia) and inexperience of the institution or operator with performing intracranial mechanical thrombectomy using CS. The conversion from CS to GA might lead to additional delays in the CS group. Every 5‐minute delay in the start of endovascular reperfusion has been estimated to worsen the clinical outcome for 1 in 100 patients.[34](#jah34168-bib-0034){ref-type="ref"} Thus, the high rate of conversion could have reduced the effect of endovascular treatment in the CS group.

Fifth, although there were many similarities to the methodology of the included RCTs, there was also some variability, including eligibility criteria, and the type of devices used for endovascular therapy, which may have a significant influence on outcomes. However, we were unable to assess the effect of important variables because of only 3 trials being included in this review.

Sixth, all included trials were not double‐blind study group assignments. Thrombectomy technique, such as the use of a stent retriever, and direct thrombus aspiration, was at the discretion of the neuro‐interventionists, which could have introduced bias if patients were treated differently based on knowledge of their assignment.

Conclusions {#jah34168-sec-0029}
===========

In contrast with previous meta‐analyses of observational studies, this systematic review and meta‐analysis found that GA provides beneficial functional independence during endovascular treatment for acute ischemic stroke, compared with CS. Further large RCTs are required to confirm the benefit.
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